相关实验视频
Updated: May 2, 2026

08:24
Bioinspired Soft Robot with Incorporated Microelectrodes
Published on: February 28, 2020
8.6K
引入一款灵活的聚合物心脏门假肢,其特殊设计适用于额头位置
Sabine H Daebritz1, Jörg S Sachweh, Benita Hermanns
1Department of Cardiac Surgery, Ludwig-Maximilians-University, University Hospital Grosshadern, Munich, Germany. sabine.daebritz@hch.med.uni-muenchen.de
Circulation
|September 13, 2003
概括
一种新的聚碳乙烯 (PCU) 胆叶片心脏假体,用于配心置换,在动物研究中显示出出色的性能和耐用性,性能优于传统的生物假体. 这种创新型的 mitra 门假体显示了减少化和退化.
科学领域:
- 生物材料科学 生物材料科学
- 心血管外科心血管外科
- 医疗器械 医疗器械
背景情况:
- 目前的心脏门假肢模仿大动脉,忽视了独特的中心膜血液动力学.
- 一种新型的聚碳乙烯 (PCU) 胆叶假肢是专门为 mitra 位置设计的.
- 本研究介绍了PCU假肢,并介绍了最初的动物测试结果.
研究的目的:
- 为了评估一个新的PCU胆叶片假肢的血液动力学性能和耐用性.
- 在动物模型中比较PCU假肢与商业生物假肢的疗效和安全性.
- 评估PCU中膜假体的体内结构完整性和生物相容性.
主要方法:
- 在体外耐用性测试证实>15年的功能.
- 七个PCU假肢和七个商业生物假肢被植入成长小牛的头部位置20周.
- 进行了植入后和牺牲前的二维心声学,以及尸检 (组织学,放射学,电子显微镜).
主要成果:
- PCU门在植入后没有显著的梯度或反,小牛的临床结果很好.
- 相比之下,7只带有生物假体的小牛中有5只需要在9周内因为心力衰竭而牺牲.
- 20周后,PCU门表现出轻微的叶片加厚和微不足道的反 (平均梯度8.1±5.0 mmHg),轻微的化和没有结构退化.
- 解释生物假体显示严重的化/退化 (Perimount) 或血栓形成/退化 (Mosaic).
结论:
- 与当前的生物假体相比,中枢PCU假体表现出优越的血液动力性能和体内耐用性.
- PCU门显著减少了化和结构退化.
- 计划进行进一步的受控临床研究,以验证这些研究结果在人类患者身上.
相关概念视频
Mitral Valve Prolapse I: Introduction
1.1K
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
1.1K
Mitral Valve Prolapse II: Assessment and Management
1.4K
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
1.4K
Mitral Regurgitation I: Introduction
1.3K
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
1.3K
Mitral Regurgitation III: Medical Management
686
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
686
Mitral Stenosis I: Introduction
1.8K
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.8K
Mitral Stenosis III: Medical Management
535
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
535

